Comparison of characteristics and outcomes on ETP-ALL/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation

Juan Chen; Li Liu; Runzhi Ma; Aiming Pang; Donglin Yang; Xin Chen; Jialin Wei; Yi He; Rongli Zhang; Weihua Zhai; Qiaoling Ma; Erlie Jiang; Mingzhe Han; Sizhou Feng

doi:10.3389/fonc.2022.1025885

Comparison of characteristics and outcomes on ETP-ALL/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation

Front Oncol. 2023 Jan 4:12:1025885. doi: 10.3389/fonc.2022.1025885. eCollection 2022.

Authors

Juan Chen^{1

2

3}, Li Liu¹, Runzhi Ma¹, Aiming Pang¹, Donglin Yang¹, Xin Chen¹, Jialin Wei¹, Yi He¹, Rongli Zhang¹, Weihua Zhai¹, Qiaoling Ma¹, Erlie Jiang¹, Mingzhe Han¹, Sizhou Feng¹

Affiliations

¹ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
² Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Soochow University, Suzhou, China.
³ Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Collaborative Innovation Center of Hematology, Suzhou, China.

Abstract

Objective: This study aims to compare the characteristics of early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) and non-ETP ALL patients and the outcomes of these patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Method: A total of 57 patients with T-cell acute lymphoblastic leukemia/lymphoma receiving allo-HSCT at our center between January 2016 and March 2022 were enrolled in the study. Twenty-eight patients were diagnosed as ETP-ALL/LBL (28/57, 49.12%) in the cohort.

Results: The baseline characteristic was not significantly different between the two groups. The median time for myeloid engraftment was 14 days (ranged from 11 to 21) versus 14 days (ranged from 10 to 20) (P = 0.067) and 18 days (ranged from 12 to 27) versus 15.5 days (ranged from 12 to 72) (P = 0.183) for platelet engraftment in the ETP-ALL/LBL and non-ETP ALL groups, respectively. There was no significant difference in 5-year overall survival (54.74% ± 10.33% vs. 64.20% ± 10.30%, P = 0.786), relapse-free survival (56.22% ± 10.11% vs. 57.17% ± 12.71%, P = 0.841), cumulative incidence of relapse (30.14% ± 9.85% vs. 22.79% ± 8.24%, P = 0.774), and non-relapse mortality (19.52% ± 8.99% vs. 25.95% ± 14.44%, P = 0.967) between the two groups. The incidence of acute graft versus host disease (aGVHD) (P = 0.922), II-IV aGVHD (P = 0.940), III-IV aGVHD (P = 0.664), cytomegalovirus infection (P = 0.862), Epstein-Barr virus infection (P = 0.610), and severe bacterial infection (P = 0.145) was also similar.

Conclusion: The prognosis of patients with ETP-ALL/LBL was similar to non-ETP ALL patients when they received allo-HSCT.

Keywords: acute lymphoblastic leukemia; allogeneic hematopoietic stem cell transplantation; characteristics; early T-cell precursors; prognosis.